Abstract 10340: Higher Prevalance of Non-Group 1 Pulmonary Hypertension in Admissions Among Cancer Survivors with Worse In-Hospital Outcomes- A Nationwide Analysis
| Autor: | Bisharah Rizvi, Srija Shanker, Mimoza Isufi, Ashish Nepal, Deepu Joseph, Tanvi Singla, Aamer Mohammad, Zainab Gandhi, Rupak Desai |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Circulation. 144 |
| ISSN: | 1524-4539 0009-7322 |
| DOI: | 10.1161/circ.144.suppl_1.10340 |
| Popis: | Introduction: Pulmonary hypertension (PH) in cancer patients is an underrecognized problem. It can be secondary to malignancy, medications, thromboemboli in lung, and underlying cardiac or lung disease. Outcomes of PH in cancer survivors have not been studied before. The objective of this study is to study the prevalence and impact of Non-group 1 PH on admissions among cancer survivors. Methods: The National Inpatient Sample (October, 2015 to 2017), was used to identify all adult hospitalizations among cancer survivors with PH using ICD-10 codes. Primary outcome were prevalence and demographics of PH in cancer survivors. Secondary outcomes were in-hospital mortality and healthcare resource utilization. Results: Of 6,003,538 weighted nationwide admissions of cancer survivors, 4.7% (282,810) had non-group 1 PH. The prevalence of PH was higher in patients with prior cancers compared to other admissions (4.7% vs. 3.3%, p(Fig. 1) . Hypertension, Diabetes, smoking, obesity, renal failure, congestive heart failure, valvular heart disease and chronic pulmonary disease were higher in PH group. In-hospital outcomes in cancer survivors with vs. without PH showed significantly higher all-cause inpatient mortality in PH group (OR1.34, 95% CI=1.31-1.37, p Conclusion: This is the first large-scale study to demonstrate the higher burden and worse in-hospital outcomes of non-group 1 PH in cancer survivors. Early diagnosis and treatment is necessary. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|